(Q38844945)

6 September 2017

1 reference

title

Further understanding of the pathology of glioma: implications for the clinic (English)

1 reference

6 September 2017

author name string

Sandra Camelo-Piragua

series ordinal

1

1 reference

6 September 2017

Santosh Kesari

series ordinal

2

1 reference

6 September 2017

publication date

26 May 2016

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

6 September 2017

published in

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

9

1 reference

6 September 2017

page(s)

1055-1065

1 reference

Genetic pathways to glioblastoma: a population-based study

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The definition of primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Correlation among pathology, genotype, and patient outcomes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Molecular pathogenesis of oligodendroglial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Expanding chemical biology of 2-oxoglutarate oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Insulator dysfunction and oncogene activation in IDH mutant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The power and the promise of DNA methylation markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Interlaboratory comparison of IDH mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

A vaccine targeting mutant IDH1 induces antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Understanding TERT Promoter Mutations: A Common Path to Immortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Rapid Intraoperative Molecular Characterization of Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Mutational landscape and clonal architecture in grade II and III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Possibilities of new therapeutic strategies in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Advances in the treatment of pediatric brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Chemotherapy for brain stem gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Targeted therapy for BRAFV600E malignant astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Systemic treatment for BRAF-mutant melanoma: where do we go next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Radial glia cells are candidate stem cells of ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Molecular staging of intracranial ependymoma in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194755

10.1080/14737175.2016.1194755

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference